Cargando…

COMPARISON OF TWO DIFFERENT METHODS FOR TIGECYCLINE SUSCEPTIBILITY TESTING IN ACINETOBACTER BAUMANNII

SUMMARY – Tigecycline susceptibility testing (TST) presents a tremendous challenge for clinical microbiologists. Previous studies have shown that the Epsilometer test (E-test) and Vitek 2 automated system significantly overestimate the minimum inhibitory concentrations for tigecycline resistance com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bedenić, Branka, Cavrić, Gordana, Vranić-Ladavac, Mirna, Barišić, Nada, Karčić, Natalie, Tot, Tatjana, Presečki-Stanko, Aleksandra, Lukić-Grlić, Amarela, Frančula-Zaninović, Sonja, Sreter, Katherina Bernadette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2018
Materias:	Original Scientific Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544113/ https://www.ncbi.nlm.nih.gov/pubmed/31168197 http://dx.doi.org/10.20471/acc.2018.57.04.02

Ejemplares similares

FALSE POSITIVE PHENOTYPIC DETECTION OF METALLO-BETA-LACTAMASES IN ACINETOBACTER BAUMANNII
por: Bedenić, Branka, et al.
Publicado: (2019)

1200. Molecular Epidemiology of Cephalosporinases and Extended Spectrum β-Lactamases (ESBLs) in Proteus mirabilis Isolates From Croatia: Following the Spread of Resistance Determinants Between Long-Term Care Facilities and the Community
por: Mestrovic, Tomislav, et al.
Publicado: (2018)

Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic
por: Pustijanac, Emina, et al.
Publicado: (2023)

A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
por: Mitteregger, Dieter, et al.
Publicado: (2022)

The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii
por: Li, Liping, et al.
Publicado: (2020)

Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023)

Reply to Muntean et al. Comment on “Mitteregger et al. A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A. Pathogens 2022, 11, 482”
por: Mitteregger, Dieter, et al.
Publicado: (2022)

The effect of standard-dose wintertime vitamin D supplementation on influenza infection in immunized nursing home elderly residents
por: Godan Hauptman, Ana, et al.
Publicado: (2021)

Role of efflux pumps in reduced susceptibility to tigecycline in Acinetobacter baumannii
por: Ardehali, S.H., et al.
Publicado: (2019)

Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii
por: Jo, Jeongwoo, et al.
Publicado: (2021)

Management of Measurable Variable Cardiovascular Disease' Risk  Factors
por: Frančula-Zaninović, Sonja, et al.
Publicado: (2018)

Management of Cardiac Patients in Epidemic Outbreak
por: Nola, Iskra Alexandra, et al.
Publicado: (2022)

Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
por: Shin, Jung Ar, et al.
Publicado: (2012)

Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of Acinetobacter baumannii
por: Hornsey, Michael, et al.
Publicado: (2018)

Characterization of Increased Extracellular Vesicle-Mediated Tigecycline Resistance in Acinetobacter baumannii
por: Cho, Hyejin, et al.
Publicado: (2023)

The Mechanism of Tigecycline Resistance in Acinetobacter baumannii Revealed by Proteomic and Genomic Analysis
por: Liu, Cunwei, et al.
Publicado: (2023)

Diversity of Oxacillinases and Sequence Types in Carbapenem-Resistant Acinetobacter baumannii from Austria
por: Grisold, Andrea J., et al.
Publicado: (2021)

Delirium induced by tigecycline treatment for Acinetobacter baumannii infection: A case report
por: Zheng, Xiaoying, et al.
Publicado: (2019)

Comparative Genomic Analysis of 19 Clinical Isolates of Tigecycline-Resistant Acinetobacter baumannii
por: Liu, Lin, et al.
Publicado: (2020)

Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis
por: Oliveira, Priscila R., et al.
Publicado: (2020)

Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients
por: Zhang, Jiangang, et al.
Publicado: (2022)

Alteration of adeS Contributes to Tigecycline Resistance and Collateral Sensitivity to Sulbactam in Acinetobacter baumannii
por: Yang, Yunxing, et al.
Publicado: (2023)

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii
por: Principe, Luigi, et al.
Publicado: (2009)

Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Madadi-Goli, Nahid, et al.
Publicado: (2017)

Confronting Tigecycline-Resistant Acinetobacter baumannii via Immunization Against Conserved Resistance Determinants
por: Chiang, Ming-Hsien, et al.
Publicado: (2020)

Synergistic Antibacterial Effect of Casein-AgNPs Combined with Tigecycline against Acinetobacter baumannii
por: Chen, Yu-Hsuan, et al.
Publicado: (2021)

Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination
por: Sato, Yoshinori, et al.
Publicado: (2021)

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2021)

Role of Efflux Pumps in Reduced Susceptibility to Tigecycline among Clinical Isolates of Acinetobacter baumannii
por: Mahapatra, Ashoka, et al.
Publicado: (2022)

Multidrug-Resistant Bacteria in a COVID-19 Hospital in Zagreb
por: Bedenić, Branka, et al.
Publicado: (2023)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

First Description of Colistin and Tigecycline-Resistant Acinetobacter baumannii Producing KPC-3 Carbapenemase in Portugal
por: Caneiras, Cátia, et al.
Publicado: (2018)

Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant Acinetobacter baumannii
por: Nagarajan, Deepesh, et al.
Publicado: (2019)

Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
por: Zhou, Yangang, et al.
Publicado: (2019)

Evaluation of the synergistic effect of a combination of colistin and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Kaya, Ilkem Acar, et al.
Publicado: (2017)

Two Cases Report of Intrathecal Tigecycline Therapy for Intracranial Infection with Acinetobacter baumannii and Review of Literatures
por: Huang, Guanlin, et al.
Publicado: (2022)

Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf
por: Hua, Xiaoting, et al.
Publicado: (2021)

Tigecycline Suppresses the Virulence Factors of Multidrug-Resistant Acinetobacter baumannii Allowing Human Neutrophils to Act
por: Sato, Yoshinori, et al.
Publicado: (2022)

Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia
por: Deng, Yanling, et al.
Publicado: (2022)

Multiple heteroresistance to tigecycline and colistin in Acinetobacter baumannii isolates and its implications for combined antibiotic treatment
por: Jo, Jeongwoo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_svc6tkarcv5nmc7rf7l8ujumfh